LC-MS Identity Confirmation: What the Mass Spectrum Proves About a Peptide

Research-use-only context. This article summarizes published third-party scientific literature and laboratory practice. It is not medical advice, not a therapeutic or performance claim, and not a usage guide. US Prime Peptides products are supplied strictly for in vitro laboratory research and are not for human or veterinary use.

The identity line on a peptide certificate usually reads "Conforms by LC-MS" with an observed mass next to a theoretical one. This article explains what that comparison proves, how the mass spectrometer arrives at the number, what charge states and isotope patterns look like in the raw data, and which questions about a peptide a mass spectrum cannot answer.

What LC-MS identity confirmation is

LC-MS identity confirmation is a test that separates a peptide sample by liquid chromatography, ionizes what elutes, measures the mass-to-charge ratio of the ions, and compares the resulting molecular mass to the mass calculated from the declared sequence. If the observed mass matches the theoretical mass within the instrument's tolerance, the sample is reported as conforming to the stated identity. The test answers one question: does the main component of this vial have the molecular mass that the named peptide should have?

Two instruments do the work in series. The liquid chromatograph, usually the same reversed-phase column that produces the purity figure described in HPLC Purity: What Area Percent Does and Does Not Tell You, spreads the sample out in time so that the main peptide reaches the detector apart from most impurities. The mass spectrometer then measures the ions in that peak. USP General Chapter <621> governs the chromatographic side of the method, including system suitability, and USP <1225> classifies identification tests as its own validation category (Category IV), in which specificity is the parameter that matters.

A 2015 AAPS Journal paper from an FDA analytical laboratory, by Zeng and colleagues, describes what a modern version of this test can do when a high-resolution instrument is used: confirm sequence, determine amino acid composition, and detect related impurities below 0.1 percent of the main component in a single run, using salmon calcitonin, bivalirudin and exenatide as the model peptides.

Expected mass: what the certificate is comparing against

The theoretical mass is calculated from the sequence by adding the residue masses of each amino acid, adding one molecule of water for the free termini, and then adjusting for any modification such as C-terminal amidation (which replaces OH with NH₂, a loss of 0.984 Da) or N-terminal acetylation (an addition of 42.011 Da). Two conventions exist and a certificate should say which it uses.

The monoisotopic mass uses the mass of the most abundant isotope of each element (¹²C, ¹H, ¹⁴N, ¹⁶O, ³²S). The average mass uses the natural-abundance weighted mass of each element. For a small peptide the two differ by less than 1 Da; for a 4,000 Da peptide they differ by about 2.5 Da. High-resolution instruments report monoisotopic mass; older or lower-resolution instruments report average mass from an unresolved envelope.

Note what the theoretical mass does not include: the counter-ion. A trifluoroacetate or acetate salt dissociates on ionization, so the observed mass is that of the peptide itself. The salt form appears in the net peptide content line, not the identity line; see TFA Salt vs Acetate Salt for that distinction.

Electrospray and charge states

Peptides are brought into the gas phase by electrospray ionization, a method that John Fenn and colleagues described in a 1989 Science paper. The liquid eluting from the column is sprayed through a charged capillary; the droplets shrink as solvent evaporates and release ions carrying one or more protons. Because a peptide has several basic sites (the N-terminus, lysine, arginine, histidine), it usually carries more than one charge, and the spectrometer measures mass-to-charge ratio (m/z), not mass.

The relation is m/z = (M + n × 1.00728) / n, where M is the neutral monoisotopic mass, n is the number of protons and 1.00728 Da is the proton mass. A single peptide therefore appears as a series of peaks, one for each charge state, and the software "deconvolutes" them back to a single neutral mass. The table shows the series for the two peptides above.

A certificate that lists "observed m/z 710.4 (2+)" for BPC-157 is reporting the doubly charged ion; a certificate that lists "observed mass 1418.7" is reporting the deconvoluted neutral mass. Both are correct. What should not appear is a mismatch between the stated charge and the number, which is a sign the line was copied rather than read from the spectrum.

Isotope patterns and resolution

At high resolution, each charge state resolves into a cluster of peaks spaced 1/z apart, because about 1.1 percent of carbon atoms are ¹³C. For a peptide with 62 carbons, roughly half the molecules contain at least one heavy isotope, so the monoisotopic peak is accompanied by peaks at +1, +2 and +3 Da of decreasing height. Above about 2,000 Da the +1 peak becomes taller than the monoisotopic peak, and the analyst must be sure which peak is being reported. Senko, Beu and McLafferty addressed this in a 1995 Journal of the American Society for Mass Spectrometry paper that introduced the "averagine" model, an average amino-acid composition used to predict the isotope distribution for a given mass so that the monoisotopic peak can be identified correctly.

The spacing of the isotope peaks is itself a check on the charge state: peaks 0.5 Da apart mean z = 2, peaks 0.33 Da apart mean z = 3. A certificate should name the instrument type; a mass accuracy of a few parts per million is typical of time-of-flight and Orbitrap analyzers, while a quadrupole is accurate to roughly 0.1 to 0.5 Da.

Mass accuracy sets the strength of the identity statement. He, Emmett, Håkansson, Hendrickson and Marshall showed in a 2004 Journal of Proteome Research paper that even very accurate mass alone cannot uniquely identify a peptide among all possible sequences, because many compositions share a mass within one part per million. For a synthetic peptide the question is narrower, since the candidate sequence is known, but the principle holds: a matching mass is consistent with the declared identity, not a proof of the sequence.

What the mass spectrum cannot distinguish

A mass spectrum confirms composition, not arrangement or stereochemistry. The main blind spots are listed below, with the analytical method that closes each gap.

The stereochemistry gap is the one most often overlooked. Solid-phase synthesis can racemize certain residues, especially histidine and cysteine, during coupling. The resulting epimer has exactly the same formula and mass, often the same retention time, and is invisible to an intact-mass test. Jia, Lietz, Yu and Li demonstrated in a 2014 Analytical Chemistry paper that ion-mobility spectrometry of MS-generated fragment ions can locate a D-amino acid within a peptide, using epimers of melanocyte-stimulating hormone and deltorphin as test cases. That is a research method, not a routine certificate test. D'Hondt and colleagues catalogued epimers, deletion sequences, deamidation products and other related impurities in a 2014 Journal of Pharmaceutical and Biomedical Analysis review that remains the reference list for what can go wrong in a synthetic peptide.

Sequence confirmation requires tandem mass spectrometry, in which the parent ion is fragmented and the b- and y-ion series read like a ladder. Shevchenko and colleagues described de novo sequencing by nanoelectrospray quadrupole time-of-flight MS in a 1997 Rapid Communications in Mass Spectrometry paper. Some certificates include an MS/MS sequence coverage statement; most research-grade certificates do not, and report intact mass only.

Reading the identity line on a certificate

A complete identity line names the method, the instrument class, the theoretical mass with its convention, the observed mass or m/z with its charge state, and the acceptance tolerance. Anything less is a conclusion without the data behind it. The checklist below gives the questions to ask of each element.

The FDA's 2017 Federal Register notice announcing its draft guidance on highly purified synthetic peptides set the regulatory expectation that peptide-related impurities be characterized by methods capable of resolving them, with LC-MS as the primary tool; the same standard of transparency is reasonable to ask of any research-grade report. A certificate from US Prime Peptides lists identity by mass spectrometry alongside HPLC purity, net peptide content and the contaminant panel for each lot. The companion article on what a certificate does not test for covers the remaining blind spots, and the line-by-line certificate guide walks through the full document.

Frequently Asked Questions

What does "identity confirmed by LC-MS" mean on a peptide COA?

It means the laboratory separated the sample by liquid chromatography, measured the mass-to-charge ratio of the main peak by mass spectrometry, and found that the deconvoluted mass matches the mass calculated from the declared sequence within the instrument's tolerance. It confirms molecular composition, not sequence order or stereochemistry.

Why does a peptide show several peaks in a mass spectrum?

Electrospray ionization gives a peptide one or more protons, so a single molecule appears as a series of ions at different charge states, each at m/z = (M + n × 1.00728) / n. Within each charge state, natural ¹³C produces an isotope cluster spaced 1/z apart. Software deconvolutes the series back to one neutral mass.

Can mass spectrometry tell D-amino acids from L-amino acids?

Not by intact mass. D and L forms of a residue have identical mass, so an epimer is invisible to a standard identity test. Detecting one requires chiral amino acid analysis after hydrolysis or specialized ion-mobility methods such as the one Jia and colleagues described in 2014.

What is the difference between monoisotopic and average mass?

Monoisotopic mass uses the lightest major isotope of each element and corresponds to the first peak in a resolved isotope cluster. Average mass weights each element by natural isotope abundance and corresponds to the centroid of an unresolved envelope. For a 4,000 Da peptide they differ by about 2.5 Da, so a certificate should state which it reports.

Citations

1. Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM. Electrospray ionization for mass spectrometry of large biomolecules. Science. 1989;246:64-71. PMID 2675315
2. Senko MW, Beu SC, McLafferty FW. Determination of monoisotopic masses and ion populations for large biomolecules from resolved isotopic distributions. J Am Soc Mass Spectrom. 1995;6:229-233. PMID 24214167
3. Zeng K, Geerlof-Vidavisky I, Gucinski A, Jiang X, Boyne MT. Liquid Chromatography-High Resolution Mass Spectrometry for Peptide Drug Quality Control. AAPS J. 2015;17:643-651. PMID 25716148
4. He F, Emmett MR, Håkansson K, Hendrickson CL, Marshall AG. Theoretical and experimental prospects for protein identification based solely on accurate mass measurement. J Proteome Res. 2004;3:61-67. PMID 14998164
5. Jia C, Lietz CB, Yu Q, Li L. Site-specific characterization of (D)-amino acid containing peptide epimers by ion mobility spectrometry. Anal Chem. 2014;86:2972-2981. PMID 24328107
6. D'Hondt M, Bracke N, Taevernier L, et al. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014;101:2-30. PMID 25044089
7. Shevchenko A, Chernushevich I, Ens W, et al. Rapid 'de novo' peptide sequencing by a combination of nanoelectrospray, isotopic labeling and a quadrupole/time-of-flight mass spectrometer. Rapid Commun Mass Spectrom. 1997;11:1015-1024. PMID 9204576
8. Melanson JE, Thibeault MP, Stocks BB, Leek DM, McRae G, Meija J. Purity assignment for peptide certified reference materials by combining qNMR and LC-MS/MS amino acid analysis results: application to angiotensin II. Anal Bioanal Chem. 2018;410:6719-6731. PMID 30143839
9. United States Pharmacopeia. General Chapter <621> Chromatography. USP-NF. doi.usp.org/USPNF/USPNF_M99945_40101_01.html
10. United States Pharmacopeia. General Chapter <1225> Validation of Compendial Procedures. USP 35-NF 30. archived chapter text
11. FDA. ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin; Draft Guidance for Industry; Availability. Federal Register. 2017;82:46057. govinfo.gov

This article is for laboratory research reference only. US Prime Peptides products are supplied strictly for in vitro research. Not for human consumption.

Compliance Notice: US Prime Peptides products are supplied strictly for laboratory and academic research purposes only. They are not intended for human or veterinary consumption, diagnosis, treatment, or prevention of any disease. All content on this page is educational in nature and does not constitute medical advice or product claims. Researchers are responsible for handling these compounds in accordance with their institution’s safety protocols and applicable laws.